Do Cell Cycle Inhibitors Promote Angiogenesis by Altering the Bone Marrow Microenvironment?
Volume 4, Issue 6 June 2005 Page 618 DOI: 10.4161/cbt.4.6.1883 We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link: Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk. A biochemical partnership between two novel compounds called cell-cycle inhibitors is crucial to the development of blood vessels that help tumors survive and thrive, according to a collaborative Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center study published in the Proceedings of the National Academy of Sciences. When researchers transplanted tumors into mice genetically engineered to lack two of these inhibitors, those tumors failed to develop much-needed vasculature — a process called angiogenesis. “Mice lacking these two inhibitors of cell proliferation had pronounced defects in their ability
A biochemical partnership between two novel compounds called cell-cycle inhibitors is crucial to the development of blood vessels that help tumors survive and thrive, according to a collaborative Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center study published in the Proceedings of the National Academy of Sciences. When researchers transplanted tumors into mice genetically engineered to lack two of these inhibitors, those tumors failed to develop much-needed vasculature — a process called angiogenesis. “Mice lacking these two inhibitors of cell proliferation had pronounced defects in their ability to mobilize bone marrow stem cells and adjacent blood vessels to create new blood vessels which support both spontaneous tumors and those implanted into the mice,” explained co-senior researcher Dr. Andrew Koff, Head of the Cell Cycle Regulation Laboratory at Memorial Sloan-Kettering Cancer Center in New York City. “This is the first time that anyone has
